Brind.

Aquestive received $75m in strategic funding from RTW Investments for its Anaphylm prodrug candidate.

1 report, 1 independent Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aquestive received $75m in strategic funding from RTW Investments for its Anaphylm prodrug candidate.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Pharmaceutical TechnologyAquestive signs $75m agreement for launch of Anaphylm Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm (epinep